Abstract
Dysfunction of the hypothalamo-pituitary gonadal (HPG) axis may result in a variety of disorders, ranging from precocious puberty to infertility. Current therapies for such disorders have varying degrees of success, and are associated with adverse effects and / or practical limitations. The recent identification of Kisspeptin as a critical regulator of reproduction, may offer a new avenue for therapeutically manipulating the HPG axis. This article provides a synopsis of the role of Kisspeptin and the Kisspeptin receptor in reproduction, with an emphasis on potential areas of its exploitation as a therapeutic or diagnostic tool. This article also reviews some of the recent patents related to the field.
Keywords: Kisspeptin, metastin, GPR54, gonadotrophin, infertility, hypothalamus, GnRH
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title: Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Volume: 3 Issue: 2
Author(s): Channa N. Jayasena, George Tharakan and Waljit S. Dhillo
Affiliation:
Keywords: Kisspeptin, metastin, GPR54, gonadotrophin, infertility, hypothalamus, GnRH
Abstract: Dysfunction of the hypothalamo-pituitary gonadal (HPG) axis may result in a variety of disorders, ranging from precocious puberty to infertility. Current therapies for such disorders have varying degrees of success, and are associated with adverse effects and / or practical limitations. The recent identification of Kisspeptin as a critical regulator of reproduction, may offer a new avenue for therapeutically manipulating the HPG axis. This article provides a synopsis of the role of Kisspeptin and the Kisspeptin receptor in reproduction, with an emphasis on potential areas of its exploitation as a therapeutic or diagnostic tool. This article also reviews some of the recent patents related to the field.
Export Options
About this article
Cite this article as:
Jayasena N. Channa, Tharakan George and Dhillo S. Waljit, Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2009; 3 (2) . https://dx.doi.org/10.2174/187221409788452354
DOI https://dx.doi.org/10.2174/187221409788452354 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Astrocytes as a 5-HT2B-Mediated SERT-Independent SSRI Target, Slowly Altering Depression-Associated Genes and Function
Current Signal Transduction Therapy Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Synthesis, Molecular Docking Study, and Cytotoxic Activity of 3,4-diaryl-5-(4-pyridinyl)-1,2,4-oxadiazole
Medicinal Chemistry